Summit Therapeutics Inc. stocks have been trading up by 7.72 percent after promising clinical progress fueled bullish investor sentiment.
Click Here for a Millionaire's POV on Trading SMMT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Ivonescimab plus chemotherapy cut risk of death by 34% versus tislelizumab combos in first-line squamous NSCLC, with Phase III HARMONi-6 data in The Lancet and highlighted at ASCO 2026.
- Phase II colorectal cancer data for ivonescimab plus mFOLFOX6 showed 70.8% objective response, 100% disease control, and durable higher-dose responses, beating historical bevacizumab+FOLFOX benchmarks.
- A Biologics License Application for ivonescimab in NSCLC is under FDA review with a November 2026 PDUFA date, creating a clear regulatory catalyst for SMMT.
- The company plans a $500M underwritten stock offering, plus a $75M greenshoe, to fund ivonescimab and general needs, adding dilution risk but strengthening the cash runway.
- Insider Manmeet Singh Soni bought 50,000 shares (~$722,250), lifting his stake above 3.1M shares, even as the stock recently slid 10.2% to $12.83 without new negative fundamentals.
Weekly Update Jun 08 – Jun 12, 2026: On Friday, June 12, 2026 Summit Therapeutics Inc. stock [NASDAQ: SMMT] is trending up by 7.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Summit Therapeutics is a late‑stage oncology developer with no revenue, deeply negative margins, and ROE below –200%, placing it at the high‑risk end of the biotech spectrum. Cash of ~$239M, minimal debt (D/E ~0.04), and a strong current ratio of 7.4 provide ~6–8 quarters of runway at the current ~$90M+ quarterly burn before the new equity raise. The $9.6B EV and ~30x P/B embed substantial expectations around ivonescimab’s success, leaving little margin for clinical or regulatory setbacks.
Weekly trading shows a sharp rebound from the $13.05–13.10 area mid‑week back to $14.09, with buyers defending the low‑$13s after a prior high‑volume selloff near $12.80. Intraday 5‑minute action (not shown numerically but implied by the reversal) indicates accumulation on upticks with heavier volume toward $14.00+. The dominant trend is short‑term up within a volatile broader uptrend. A specific actionable level: $13.00–13.20 is key support; aggressive longs can buy pullbacks there with a tight stop below $12.70.
More Breaking News
- NTSK Slips As Netskope Expands AI Compliance With Claude
- AZI Stock Whipsaws As Traders Target Volatile Setup
- ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial
- Ultra Clean Holdings (UCTT) Jumps As Oppenheimer Hikes Target On AI Boom
Fundamentally, ivonescimab now has Phase III OS‑positive data in first‑line squamous NSCLC and strong Phase II ORR in mCRC, positioning SMMT ahead of many small‑cap oncology peers and closer to large‑cap benchmarks on clinical maturity, though still far weaker on profitability. The pending US NSCLC BLA (PDUFA November 2026) and global Phase III program are major upside catalysts, partially offset by dilution from the planned $500M+75M equity raise. I see SMMT as a high‑beta outperformer with a 12–18 month upside target range of $18–20, with support at $13 and resistance near $15.50–16.00.
Quick Financial Overview
Summit Therapeutics Inc. and ticker SMMT are trading around the mid-teens after heavy clinical news flow and a sharp pullback. The recent daily candles show a rebound from $13.05 back to $14.09 over several sessions, with the latest close near the high of the week. That tells you dip buyers stepped in after the 10.2% hit to $12.83, likely viewing the selloff as profit-taking or worry about the upcoming equity deal rather than a change in the clinical story.
On the intraday tape, SMMT spent most of the session cycling between roughly $13.40 and $14.15, with a late-day push that closed near the top of the range. This type of accumulation pattern after a violent down day often signals short covering mixed with new speculative entries. For short-term traders, the $13.00–$13.20 area now looks like a key intraday support band, while the $14.20 area marks immediate resistance and a reference for breakouts.
Financially, Summit Therapeutics Inc. is a classic development-stage biotech: minimal revenue, heavy R&D, and large operating losses. The latest quarterly numbers show about -$231.8M in net loss and -$93.1M in free cash flow, backed by strong liquidity with $238.9M in cash and a high current ratio of 7.4. The enterprise value near $9.57B, price-to-book near 30.5, and deeply negative returns on equity and assets underline that traders are paying for ivonescimab’s potential, not current earnings.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.